In its annual report, issued earlier this week, the Medicare program’s trustees said that Medicare will remain solvent until 2029, allowing the program to forestall triggering an Affordable Care Act provision to convene the Independent Payment Advisory Board.
In its annual report, issued earlier this week, the Medicare program’s trustees said that Medicare will remain solvent until 2029, allowing the program to forestall triggering an Affordable Care Act (ACA) provision to convene the Independent Payment Advisory Board (IPAB).
The IPAB, a 15-member panel (or the HHS if such a panel cannot be convened), will be called upon when Medicare spending exceeds statutory benchmarks. The body will be required to provide recommendations to Congress on mandatory cost-cutting measures to control Medicare spending.
The IPAB provision of the ACA has been widely criticized by stakeholders, including the American Medical Association (AMA), which has advocated for a repeal of the provision. The AMA calls IPAB an “inflexible mandate to impose arbitrary across-the-board cuts to physicians and other providers that could adversely affect access to health care services for Medicare patients.” Pharmaceutical industry trade group PhRMA echoed the AMA’s views, saying that proposals made by IPAB would be “…likely to restrict patients’ access to needed health care services and treatments by disproportionately targeting new treatments as a way to cut spending—prioritizing cost-cutting ahead of a medicine’s benefits to patients.”
The announcement that the IPAB would not be formed this year came welcome news to the biotechnology industry, which was bracing for the board’s implementation. The 2016 report from the same body projected that 2017 spending levels would trigger the IPAB provision this summer, and many in the industry feared that IPAB’s primary recommendations to reduce Medicare costs would target expensive biologic treatments, forcing biopharmaceutical companies to make substantial price concessions on their products.
Despite broad industry criticism of IPAB, a growing bipartisan push in the House and Senate to repeal the deeply unpopular provision, and Republicans’ promises to repeal and replace the ACA, Senate healthcare reform legislation leaves the IPAB provision untouched. According to the original legislation’s language, Congress would have to pass a joint resolution to repeal the IPAB provision before August 15 of this year. Such a resolution would have to be passed by a three-fifth’s majority in both chambers, and that is an unlikely scenario as Senate Majority Leader Mitch McConnell (R-Kentucky) focuses on gaining enough votes to pass the latest version of the healthcare reform bill.
Even though IPAB will not be be enforcing mandatory cost controls on Medicaid, other deep cuts are on the way. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule, due to be published in the Federal Register on July 20, that would revise the Medicare hospital outpatient prospective payment system and the Medicare ambulatory surgical center payment system for 2018.
The rule would cut the applicable payment rate for separately payable drugs and biologics acquired under the 340B program from the average sales price (ASP) plus 6% to the ASP minus 22.5%. These cuts are part of a CMS effort to curb the growth of spending, which CMS says grew faster among hospitals that participated in the 340B program than among hospitals that did not, noting that Medicare beneficiaries at 340B hospitals were either prescribed more drugs or were prescribed more expensive drugs than were beneficiaries in other hospitals.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.